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Heme, iron (Fe) protoporphyrin IX, functions as a prosthetic group in a range of hemo-
proteins essential to support life under aerobic conditions. The Fe contained within the
prosthetic heme groups of these hemoproteins can catalyze the production of reactive
oxygen species. Presumably for this reason, heme must be sequestered within those
hemoproteins, thereby shielding the reactivity of its Fe-heme. However, under pathologic
conditions associated with oxidative stress, some hemoproteins can release their pros-
thetic heme groups.While this heme is not necessarily damaging per se, it becomes highly
cytotoxic in the presence of a range of inﬂammatory mediators such as tumor necrosis
factor. This can lead to tissue damage and, as such, exacerbate the pathologic outcome
of several immune-mediated inﬂammatory conditions. Presumably, targeting “free heme”
may be used as a therapeutic intervention against these diseases.
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PHYSIOLOGICAL ROLE OF HEME
Heme acts as prosthetic group in a range of hemoproteins that
play a pivotal role in many essential biological processes. These
include gas transport and storage, mitochondrial electron trans-
port chain, drug metabolism, signal transduction and regulation
of gene expression (Chapman et al., 1997).
STRUCTURE AND BIOCHEMISTRY OF HEME
Heme is a hydrophobic metallo-compound containing a Fe atom
within its protoporphyrin ring. It is composed of four methane-
bridged pyrroles (tetrapyrrole ring) bound to the central Fe atom
through nitrogen atoms (Reedy and Gibney, 2004; Kumar and
Bandyopadhyay, 2005; Tsiftsoglou et al., 2006). Ferrous (Fe2+)
heme has a neutral chemical charge, whereas ferric (Fe3+) heme
is positively charged, and can bind anions (Kumar and Bandy-
opadhyay, 2005). Although ferrous and ferric states are the most
common within the heme structure, oxidative states of Fe-heme
can vary from Fe2+ to Fe5+(Ogura et al., 1996; Karpefors et al.,
2000; Dey and Ghosh, 2002).
Heme existsmainly as a,b, and c variants,which differ by subtle
chemical modiﬁcations (Chapman et al., 1997; Tsiftsoglou et al.,
2006; Smith et al., 2010). One of the vinyl groups of heme b, is
replaced by a 17-hydroxyethylfarnesyl group in heme a. One of
the methyl groups of heme b is also replaced by a formyl group in
heme a (Caughey et al., 1975; Han et al., 1991). In heme c, both
vinyl groups of heme b are replaced by sulfhydryl groups (Bowman
and Bren, 2008). Heme b is the most common variant in mam-
mals, present, among others, in hemoglobin (Hb) and myoglobin
(Fermi et al., 1984; Evans and Brayer, 1990; Paoli et al., 1996; Park
et al., 2006). Heme a and c are found in cytochrome c oxidase and
cytochrome c, respectively (Bushnell et al., 1990; Tsukihara et al.,
1995). Whereas heme c can bind covalently to proteins, via two
thioether bonds, this is not the case for heme b and a, eventually
allowing for their release from hemoproteins (Allen et al., 2003).
HEMOPROTEINS
Hemoproteins have a diverse spectrum of biological functions.
These include transport and storage of diatomic gaseous mole-
cules such as oxygen (O2),nitric oxide (NO) and carbonmonoxide
(CO; Chay and Brillhart, 1974a,b; Aono, 2008; Kakar et al., 2010).
They are also essential for electron transfer reactions (Makinen
et al., 1983; Gray and Winkler, 1996) as well as for modulation
of gene transcription (Tahara et al., 2004a,b; Youn et al., 2006;
Hira et al., 2007), such as involved in the regulation of circadian
rhythms (Kaasik and Lee, 2004). Prosthetic heme groups have also
been implicated in the regulation of signal transduction pathways
(Igarashi and Sun, 2006; Zenke-Kawasaki et al., 2007), ion-channel
functions (Tang et al., 2003; Horrigan et al., 2005), micro-RNA
processing (Faller et al., 2007) and the metabolism of xenobiotics
and drugs (Bernhardt, 1996; Rowland et al., 2006).
Under physiologic conditions, heme is found mainly in the
“hemepockets”of hemoproteins. These are characterized by a high
frequency in aromatic amino acids (Table 1), such as phenylala-
nine (F), tyrosine (Y) or tryptophan (W) and by few or no charged
amino acids (Li et al., 2011), conferring the hydrophobicity
required to promote stable heme binding to hemoproteins. Five
highly conserved amino acids, including histidine (H), methio-
nine (M), cysteine (C), tyrosine (Y) and lysine (K) can act as
axial heme ligands in the heme pockets of hemoproteins (Li et al.,
2011). Of these, H is frequently found in hemoproteins contain-
ing heme c or b (Table 1). Moreover, C often promotes binding
of heme b, whereas M binds heme c (Fufezan et al., 2008; Li et al.,
2011; Table 1). Other hydrophobic amino acids such as leucine
(L), isoleucine (I) and valine (V) can also create interactions with
the porphyrin structure of heme, whereas arginine (R) and other
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Table 1 | Selected representatives of Mammalian hemoproteins and heme-sensing proteins.
Function Representative hemoprotein Number/type of heme Axial ligand References
Electron transport Cytochrome c 1/c-type His, Met Mirkin et al. (2008)
Cytochrome b5 1/b-type His, His Wirtz et al. (2000)
Cytochrome c oxidase 2/a-type His/Vacant, His/His Tsukihara et al. (1995)
Cytochrome c reductase 2/b-type, 1/c-type His/His, His/His, His/Met Xia et al. (1997); Zhang et al. (1998)
Gas carriers Hemoglobin 4/b-type His, Vacant Park et al. (2006)
Myoglobin 1/b-type His, Vacant Evans and Brayer (1988); Vojtechovsky
et al. (1999)
Catalytic
activity – enzyme
Catalase I 1/b-type Tyr, Vacant Putnam et al. (2000)
Cytochrome P450 1/b-type Cys, Vacant or water Rowland et al. (2006)
Indoleamine 2,3-dioxygenase 1/b-type His, ligand Sugimoto et al. (2006)
NO synthase 2/b-type Cys, Vacant Crane et al. (1997)
Cystathionine β-synthase 1/b-type Cys/His Meier et al. (2001)
Tryptophan 2,3-dioxygenase 4/b-type His/Vacant Zhang et al. (2007b)
Transient heme
binding
Heme oxygenase 1/b-type His,Water Lad et al. (2003)
Hemopexin 1/b-type His/His Paoli et al. (1999)
Albumin 1/b-type Tyr/Vacant Wardell et al. (2002)
Heme-sensing/
heme regulated
NPAS2 2/b-type His/Cys or His/His, His/? Dioum et al. (2002); Uchida et al. (2005)
Iron regulatory protein 2 (IRP2) 1 Cys/? Jeong et al. (2004)
Soluble guanylyl cyclase 1/b-type His/Vacant Ma et al. (2007)
Under physiologic conditions, heme is found mainly in the “heme pockets” of hemoproteins, characterized by a high frequency in aromatic amino acids, e.g., pheny-
lalanine (F), tyrosine (Y) or tryptophan (W) and few or no charged amino acids (Li et al., 2011), that confer hydrophobicity, required to promote stable heme binding to
hemoproteins. Five highly conserved amino acids, including histidine (H), methionine (M), cysteine (C), tyrosine (Y) and lysine (K) can act as axial heme ligands in the
heme pockets of hemoproteins (Li et al., 2011). Of these, H is frequently found in hemoproteins containing heme c and heme b. Moreover, C often promotes binding
of heme b, whereas M binds heme c (Fufezan et al., 2008; Li et al., 2011). Other hydrophobic amino acids such as leucine (L), isoleucine (I) and valine (V) can also
create interactions with the porphyrin structure of heme, whereas arginine (R) and other positively charged amino acids interact with the negatively charged heme
proprionate groups (Schneider et al., 2007).
positively charged amino acids can interact with the negatively
charged heme propionate groups (Schneider et al., 2007).
Several heme-binding motifs have been described, namely
CXXCH and CXXCK that bind primarily heme c and in which“X”
refers to any amino acid (Fufezan et al., 2008; Smith et al., 2010;
Li et al., 2011). The GX[HR]XC[PLAV]G heme-binding motif is
associated mainly with heme b (Li et al., 2011). Another related
FXXGXXCXG motif found in mammal, cytochrome P450, as well
as in plant and bacterial hemoproteins binds to heme b (Li et al.,
2011). Other heme-binding motifs can be formed by only two
amino acids (such as the CP motif; Li et al., 2011).
In some hemoproteins, the Fe and the protoporphyrin IX ring
of heme can undergo chemical and/or electronic modiﬁcations,
such as demonstrated for peroxidases in which heme uses hydro-
gen peroxide (H2O2) to undergo several Fe oxidoreductase cycles
associated with conformational alterations of its protoporphyrin
ring. This can lead to the oxidation of neighboring molecules, e.g.,
indoles, phenols, aromatic amines, lignin, Mn2+ ions, halide ions
or proteins (Badyal et al., 2006; Zederbauer et al., 2007; Battis-
tuzzi et al., 2010). In other hemoproteins, heme does not undergo
alterations in its Fe redox state or protoporphyrin conforma-
tion (Poulos, 2007). This is the case for hemoproteins that bind
gaseous molecules such as guanylate cyclase, Hb, myoglobin or
the transcription factor neuronal PAS domain-containing protein
2 (NPAS2), among others (Chay and Brillhart, 1974a,b; Dioum
et al., 2002; Podstawka and Proniewicz, 2004; Uchida et al., 2005).
Binding of NO or CO to these hemoproteins modulates their bio-
logic activity, e.g., increased production of cGMP in the case of
guanylate cyclase (Ma et al., 2007), regulation of O2 transport in
the case of Hb or gene transcription in the case of CO binding
to NPAS2 (Dioum et al., 2002). In other instances, biologic activ-
ity is regulated by heme binding itself, as it is the case for the
transcriptional repressor Bach1 (Tahara et al., 2004a,b; Hira et al.,
2007).
HEME METABOLISM
Heme intracellular content must be tightly controlled to prevent
heme-driven cytotoxicity while assuring that heme is available
to be incorporated into nascent apo-hemoproteins. This is par-
ticularly relevant for cells with very high hemoprotein content
such as erythroid or muscle cells expressing Hb and myoglobin,
respectively. This regulatorymechanism is ensured largely through
control of heme synthesis, transport and catabolism.
HEME SYNTHESIS
Heme de novo synthesis occurs through a sequence of eight enzy-
matic steps, four of which take place in the cytoplasm and four
in the mitochondria (Figure 1; Heinemann et al., 2008). The ﬁrst
and rate-limiting step is catalyzed in the mitochondria by δ-amino
levulinic acid (ALA) synthase (ALAS), an enzyme that converts
glycine and succinyl-CoA into ALA. In most cells, heme synthe-
sis is down-regulated by heme, via inhibition of ALAS mRNA
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FIGURE 1 | Heme metabolism. Heme is synthesized from glycine and
succinyl-CoA, through eight enzymatic steps that take place in the
cytoplasm and the mitochondrion. Heme and heme precursors are
transported between these compartments by ANT and Abcb6, respectively.
In addition to the heme produced via this pathway, extracellular heme can
be imported. Hemoproteins can be taken up and denatured in endosomes,
liberating heme that can be transported to the cytoplasm via HRG-1,
whereas cell-free heme is taken up by the cell membrane-associated HCP1.
Cytoplasmic heme can be scavenged by PRX1, which neutralizes its
pro-oxidant effects. Excess heme can be exported via FLVCR and
Bcrp/Abcg2 or catabolized by HO-1/2 into equimolar amounts of BV, CO and
free Fe. BV can be converted into BR by BVR while labile cellular Fe induces
the expression of FtH that scavenges excess cellular Fe. Abbreviations:
Abcb6, ATP-binding cassette b6; ALA, δ-aminolevulinic acid; ALAD, ALA
dehydratase; ALAS, ALA synthase; ANT, adenine-nucleotide translocator;
Bcrp/Abcg2, breast cancer resistance protein/ATP-binding cassette g2; BR:
bilirubin; BV, biliverdin; BVR, BV reductase; CO, carbon monoxide; CPP,
coproporphyrinogen; CPO, CPP oxidase; Fe, iron; FECH, ferrochelatase;
FLVCR, feline leukemic virus receptor; Fth, ferritin; HCP1, heme carrier
protein-1; HMB, hydroxymethylbilane; HO, heme oxygenase; HRG-1, heme
responsive gene-1; PBG, porphobilinogen; PBGD, PBG deaminase; PP IX,
protoporphyrin IX; PPO, protoporphyrinogen oxidase; PRX1, peroxiredoxin-1;
URO, uroporphyrinogen; UROD, URO decarboxylase; UROS, URO III
synthase.
expression (Hamilton et al., 1991) or ALAS translocation from the
cytoplasm into the mitochondrion (Lathrop and Timko, 1993).
HEME TRANSPORT
Being hydrophobic, heme was assumed to diffuse passively across
cellular membranes. However, heme cellular trafﬁcking appears to
be controlled by a range of evolutionary conserved heme trans-
porters (Figure 1; reviewed in Schultz et al., 2010; Khan and
Quigley, 2011). Some of these heme transporters, e.g., mitochon-
drial ATP-binding cassette (ABC) family member, Abcb6, and the
adenine-nucleotide translocator (ANT), control the translocation
of heme as well as that of heme precursors between the cyto-
plasm and themitochondria (Figure 1; Krishnamurthy et al., 2006;
Azuma et al., 2008). Other heme transporters, including HRG-1
expressed in endosomes and lysosomes (Rajagopal et al., 2008)
or the heme carrier protein (HCP1) expressed in the cytoplasmic
membrane, control extracellular heme import (Figure 1; Shayeghi
et al., 2005; Latunde-Dada et al., 2006; Figure 1). Heme can
also be exported from cells via the ATP-binding cassette (Abcg2;
Krishnamurthy et al., 2004; Krishnamurthy and Schuetz, 2006)
and the feline leukemic virus receptor (FLVCR; Figure 1; Quigley
et al., 2000, 2004; Schultz et al., 2010).
HEME CATABOLISM
Heme degradation can be catalyzed by the enzymatic activity of
heme oxygenases (HO; Tenhunen et al., 1968. There are two iso-
forms, i.e.,HO-1 and HO-2, encoded by the HMOX1 and HMOX2
genes in humans, respectively (Figure 1; Maines et al., 1986; Trak-
shel et al., 1986). HO-2 is constitutively expressed by most cells
(Trakshel et al., 1986) and is thought to carry out heme catabolism
under homeostatic conditions. In contrast, excess intracellular
heme induces the expression of the stress-responsive HO-1 iso-
form (see HO-Catalyzed Heme Degradation), increasing the rate
of heme catabolism and, as such, preventing its putative cytotoxic
effects (Gozzelino et al., 2010). HO activity catalyzes the oxidative
cleavage of the heme protoporphyrin IX ring, yielding biliverdin
(BV), concomitant with the release of equimolar amounts of labile
Fe and carbon monoxide (CO; Figure 1; Tenhunen et al., 1968).
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Biliverdin is converted into bilirubin (BR) by BV reductase (Kutty
and Maines, 1981; Figure 1). The physiological roles of these end
products of heme catabolism, are discussed in further detail under
Section “Cellular Control of Free Heme.”
PATHOPHYSIOLOGICAL EFFECTS OF FREE HEME
Under pathophysiological conditions, heme b can be released from
hemoproteins to which it binds non-covalently (Bunn and Jandl,
1968; Hebbel et al., 1988; Pamplona et al., 2007). This produces
“free heme,” that is, heme that is not bound to the heme pockets of
hemoproteins. Free heme can act as a potent cytotoxic pro-oxidant
(Balla et al., 1992, 1993) owing to the Fe atom contained within its
protophorphyrin ring (Seixas et al., 2009; Gozzelino and Soares,
2011).
Immune-mediated inﬂammatory diseases can be associated
with the accumulation of free heme in the circulation (Reiter
et al., 2002; Pamplona et al., 2007; Seixas et al., 2009; Andrade
et al., 2010a,b; Larsen et al., 2010). The observation that free
heme can sensitize non-hematopoietic cells, e.g., hepatocytes, to
undergo programmed cell death (PCD) in response to a variety
of pro-inﬂammatory agonists (Seixas et al., 2009; Larsen et al.,
2010; Gozzelino and Soares, 2011), suggests that free heme may
participate functionally in the pathogenesis of immuno-mediated
inﬂammatory diseases (Figure 2; Francis et al., 1997), in which
the host component of inﬂammation would exacerbate the dele-
terious effects of free heme (Seixas et al., 2009; Larsen et al.,
2010; Gozzelino and Soares, 2011). Taking this into account, the
amount of circulating free heme, as a result of the overall heme
metabolism, would dictate the outcome of these pathologic con-
ditions. While free heme also appears to exert pro-inﬂammatory
effects (Figueiredo et al., 2007; Porto et al., 2007; Fernandez et al.,
2010) that might participate in the pathogenesis of immune-
mediated inﬂammatory diseases these will not be covered in
detail hereby.
Presumably, the cytotoxic effect of free heme is mediated, to a
large extent, via the unfettered production of free radicals leading
to oxidative stress. This notion is supported by the observation
that pharmacologic antioxidants can confer cytoprotection against
free heme (Seixas et al., 2009; Larsen et al., 2010). Sustained free
radicals production can prolong the activation of the c-Jun N-
terminal Kinase (JNK) signaling transduction pathway (Ventura
et al., 2004; Kamata et al., 2005), via inhibition of phosphatases
controlling JNK activation in response to tumor necrosis factor
(TNF; Davis, 2000; Sanchez-Perez et al., 2000; Masuda et al., 2001;
Tanoue et al., 2001; Kamata et al., 2005; Figure 2). The cytotoxic
effect of free heme is owed to this sustained JNK activation, as sug-
gested by the observation that heme-driven free radical production
leads to sustained JNK phosphorylation/activation (Figure 2) and
that inhibition of JNK activation affords cytoprotection against
free heme (Raffaella Gozzelino et al., unpublished results). The
cytotoxic effect of free heme is also associated with cleavage
of caspase-3, suggesting that heme sensitizes non-hematopoietic
cells, e.g., hepatocytes, to undergo PCD by apoptosis. This notion
is supported by the demonstration that pharmacologic caspase
inhibition, including speciﬁc inhibition of caspase-3, confers cyto-
protection against free heme (Figure 2; Seixas et al., 2009). More
recently, free heme has also been shown to trigger necroptosis
FIGURE 2 | Pathophysiological effects of heme. Free heme can sensitize
parenchyma cells to undergo PCD in response to pro-inﬂammatory signals
such asTNF. Under homeostatic conditions, cellular heme is degraded via
HO-1 activity and the labile Fe released in this manner, is scavenged by FtH,
thus preventing oxidative stress. Under a variety of inﬂammatory
conditions, the concentration of intracellular free heme can exceed the rate
of heme catabolism by HO-1. In addition, accumulation of cellular labile Fe
can also overcome FtH scavenging capacity. When this occurs, free heme
and/or labile Fe accumulate in cells, thereby boosting mitochondrion-driven
ROS. Activation of theTNF receptor leads to further generation of ROS,
resulting in sustained JNK activation which promotes FtH degradation
(Antosiewicz et al., 2007), leading to further labile Fe overload and hence to
further ROS generation via Fenton chemistry. Moreover, sustained JNK
activation lead to the activation of effector caspases thereby inducing PCD.
Abbreviations: FtH, ferritin; HO-1, heme oxygenase-1; JNK, c-Jun
N-terminal kinase; ROS, reactive oxygen species; TNF, tumor necrosis
factor; TNFR1, TNF receptor-1.
in hematopoietic cells, as demonstrated for macrophages (Fortes
et al., 2012).
PHYSIOLOGIC MECHANISMS OF PROTECTION AGAINST
FREE HEME
Under pathophysiologic conditions associated with intravascular
hemolysis, signiﬁcant amounts of Hb can be released from red
blood cells (RBCs). The resulting circulating cell-free Hb under-
goes oxidation, releasing its prosthetic heme groups (Bunn and
Jandl, 1968; Hebbel et al., 1988; Pamplona et al., 2007; Ferreira
et al., 2008). Similarly, oxidation of other hemoproteins, e.g.,myo-
globin, may also contribute to the unwarranted accumulation of
cytotoxic free heme, such as associated with rhabdomyolysis (Nath
et al., 1992).
Protective mechanisms are in place, on systemic as well as
cellular levels, to deal with this challenge, as described in this
section.
SYSTEMIC CONTROL OF FREE HEME
Cell-freeHb can be scavenged by haptoglobin (Hp), an acute phase
protein synthesized in the liver and present at relatively high con-
centrations (0.3–3mg/mL) in plasma (Levy et al., 2010). Binding
of Hb to Hp prevents Hb oxidation (Melamed-Frank et al., 2001)
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and thereby the release of its heme moiety (Figure 3). Hb:Hp
complexes binds to CD163 (Kristiansen et al., 2001) expressed
in macrophages and hepatocytes (Philippidis et al., 2004; Quaye,
2008), leading to endocytosis and degradation of the Hb:Hp com-
plex (Figure 3). Polymorphisms in the human HPT gene can act
as independent risk factors for several immune-mediated inﬂam-
matory diseases (Quaye, 2008), suggesting that Hb scavenging by
Hp modulates the pathogenesis of these diseases.
Under pathophysiological conditions associated with more or
less extensive intravascular hemolysis, such as malaria or differ-
ent forms of hemolytic anemia (see Heme and the Pathogenesis
of Infectious Diseases and Heme and the Pathogenesis of Non-
Infectious Immune-Mediated Inﬂammatory Conditions), extra-
cellular Hb can lead to the depletion of circulating Hp (Muller-
Eberhard et al., 1968; Rother et al., 2005). When Hb accumulates
in the circulation it becomes oxidized, releasing its heme groups
(Bunn and Jandl, 1968; Hebbel et al., 1988; Pamplona et al., 2007;
Ferreira et al., 2008).Anumberof circulatingproteins can scavenge
free heme in plasma (Bunn and Jandl, 1966; Figure 3), including
hemopexin (Paoli et al., 1999; Tolosano et al., 2010), albumin
(Fasano et al., 2007), α1-microglobulin (Allhorn et al., 2002) and
high- and low-density lipoproteins (Miller and Shaklai, 1999).
Hemopexin (Hx) is an acute phase protein present at high con-
centrations in plasma (0.6–1.2mg/mL), with the highest binding
afﬁnity for free heme (K d< 10
−12 in humans) of any described
protein (Paoli et al., 1999; Tolosano et al., 2010). Heme:Hx com-
plexes, which inhibits Fe-heme reactivity (Eskew et al., 1999), are
recognized by the macrophage CD91 receptor (Hvidberg et al.,
2005), allowing for intracellular heme catabolism (Figure 3; Alam
and Smith, 1989). Hx is not degraded by macrophages, to any sig-
niﬁcant extent, being secreted back into the circulation (Figure 3;
Hvidberg et al., 2005). As a consequence, Hx is less prone to
complete depletion from the circulation, as compared to Hp.
Mice deﬁcient in Hx and/or Hp (Hpx−/−Hpt−/−) develop
severe renal damage when subjected to hemolysis, suggesting that
Hx is part of a systemic protective mechanism against the delete-
rious effects of circulating free heme (Tolosano et al., 1999). The
reason for which the kidney appears to be the ﬁrst target of heme
cytotoxicity in vivo is not clear, but is in keeping with the obser-
vation that induction of heme catabolism prevents kidney injury
driven by rhabdomyolysis, where the hemoprotein, myoglobin, is
released into circulation (Nath et al., 1992).
Albumin can bind heme with an afﬁnity 104 times lower than
Hx (K d = 10−8; Little and Neilands, 1960). However, the high
FIGURE 3 | Mechanisms of protection against free heme. A range of
extracellular mechanisms confer protection against cell-free Hb and heme.
Under hemolytic conditions, Hb is released from RBC into the circulation
where it is scavenged by Hp, thereby preventing Hb oxidation, and allowing
for the uptake of Hb:Hp complexes via the CD163 receptor. Once the
scavenging capacity of Hp is exhausted, Hb becomes oxidized, releasing its
heme prosthetic groups. These can be scavenged by albumin, HDL and LDL,
α1-microglobulin, acting as “scavenging buffer,” and ultimately by Hx, which
has the highest afﬁnity for free heme. Hx:heme complexes are taken up via
the CD91 receptor, delivering heme for catabolism by HO-1. Intracellular
heme, whether originating from the extra- or intracellular compartment, is
degraded via HO-1. The labile Fe released from heme catabolism is
subsequently scavenged by FtH, thus conferring cytoprotection against
heme-Fe. Abbreviations: Fe, iron; FtH, ferritin; Hp, haptoglobin; Hb,
hemoglobin; HDL/LDL, high/low-density lipoprotein; Hx, hemopexin; ROS,
reactive oxygen species.
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concentration of albumin in plasma (∼43mg/mL) might com-
pensate to some extent for its low afﬁnity (Figure 3). Heme
binding to albumin can neutralize the pro-oxidant effect of free
heme,which may explain the protective effect of albumin infusion
to individuals developing severe forms of sepsis (Delaney et al.,
2011) or malaria (Maitland et al., 2005; Akech et al., 2006), the
pathogenesis of which are driven to a signiﬁcant extent by free
heme (Pamplona et al., 2007; Ferreira et al., 2008; Seixas et al.,
2009; Larsen et al., 2010; Raffaella Gozzelino et al., unpublished
results).
α1-Microglobulin is a member of the lipocalin protein super-
family, that binds small lipophilic ligands (Flower et al., 2000).
Cell-freeHb can cleave α1-microglobulin, into a truncated protein
that binds (K d = 10−6) and converts free heme into a yellow-
brown proteinaceous chromophore, subsequently cleared by renal
ﬁltration (Allhorn et al., 2002). Binding of α1-microglobulin
to heme neutralizes its pro-oxidant effect, suggesting that α1-
microglobulin acts as a heme scavenger in circulation (Figure 3;
Allhorn et al., 2002). Whether under pathophysiologic condi-
tions α1-microglobulin plays a protective role against heme is
unknown.
High- and low-density lipoproteins (HDL and LDL, respec-
tively) can bind heme (K d∼ 10
−11–10−12) with faster kinetics to
those of Hx or albumin (Miller and Shaklai, 1999), thereby acting
as the initial heme scavengers in circulation (Balla et al., 1991; Jeney
et al., 2002). Once bound to HDL and LDL, heme can be trans-
ferred to Hx (Figure 3; Morgan et al., 1976; Hvidberg et al., 2005).
In this manner, HDL and LDL may function as an initial “buffer”
for circulating heme. Binding of heme to HDL or LDL oxidizes
HDL and LDL that are then cleared via the CD36 and CD68 scav-
enger receptors expressed on macrophages (Camejo et al., 1998;
Miller and Shaklai, 1999). Of note, however, oxidized HDL and
LDL are cytotoxic (Jeney et al., 2002; Stocker and Perrella, 2006),
suggesting that heme-mediated lipid peroxidation might be a key
mechanism via which heme exerts its deleterious effects (Jeney
et al., 2002; Stocker and Perrella, 2006). This also indicates that the
beneﬁcial role of HDL and LDL in circulation would be depen-
dent on their rapid clearance that might otherwise be detrimental.
Considering its high afﬁnity for heme, Hx acts most probably as
an ultimate heme scavenger in plasma, targeting heme bound to
other carrier proteins or not, and allowing for heme delivery for
intracellular degradation by the HO system (see HO-Catalyzed
Heme Degradation).
CELLULAR CONTROL OF FREE HEME
Heme incorporation into hemoproteins
The rate of de novo heme synthesis must correspond accu-
rately to its rate of incorporation into newly synthesized apo-
hemoproteins. This is regulated at different levels via the control
of heme (see Heme Metabolism) as well as apo-hemoprotein syn-
thesis. Free heme can induce the transcription and hence the
expression of several apo-hemoproteins, as demonstrated for Hb,
myoglobin and neuroglobin in erythroid, muscle and neuronal
cells, respectively (Bruns and London, 1965; Tahara et al., 1978;
Graber andWoodworth, 1986; Zhu et al., 2002a,b). This evolution-
ary conserved strategy prevents intracellular heme accumulation,
presumably limiting heme cytotoxicity.
HO-catalyzed heme degradation
Whereas HO-2 is responsible for homeostatic heme catabolism
(see Heme Catabolism), HO-1 can be induced by different forms
of stress (Choi and Alam, 1996). Oxidative stress can lead to heme
release from hemoproteins (reviewed in Gozzelino et al., 2010),
requiring a cellular adaptive response maintaining intracellular
free heme below a cytotoxic threshold level. This is accomplished,
to a large extent, via the induction of HMOX1 transcription and
HO-1 expression (Alam et al., 1994, 1995; Choi and Alam, 1996;
Alam and Cook, 2007). In line with this notion, mouse cells deﬁ-
cient inHO-1 expression (Hmox1−/−), and thus unable to increase
heme catabolism in response to different forms of stress, display
exacerbated cytotoxicity in response to oxidative stress (Poss and
Tonegawa, 1997a,b; Yet et al., 2003; Bishop et al., 2004). Whether
this is, as speculated hereby, due to the accumulation of free heme
or whether HO-1 acts in a cytoprotective manner independently
of its ability to neutralize the cytotoxic effect of free heme, remains
unclear.
Induction of HO-1 expression in response to infection can be
essential to sustain host survival, as demonstrated for systemic
polymicrobial (Larsen et al., 2010) as well as for Plasmodium
infection (Pamplona et al., 2007; Seixas et al., 2009), the causative
agent of malaria. Accumulation of heme in the circulation is cyto-
toxic, thus leading to tissue damage and, as such, exacerbating the
pathologic outcomeof these diseases (Pamplona et al., 2007; Seixas
et al., 2009; Larsen et al., 2010). HO-1 neutralizes this cytotoxic
effect and hence provides tissue damage control and host protec-
tion against infections (Pamplona et al., 2007; Larsen et al., 2010;
reviewed in Gozzelino et al., 2010). This host defense strategy acts
irrespectively of pathogen load, a phenomenon referred to as host
tolerance to infection (Medzhitov et al., 2012).
The cytoprotective action of HO-1 (Vile et al., 1994; Soares
et al., 1998) resides not only in the degradation of cytotoxic
heme, but also in the production of the different end products
of heme catabolism, namely CO, BV, and labile Fe (Figure 3).
CO has a variety of biological effects that mitigate the patho-
genesis and/or progression of immune-mediated inﬂammatory
diseases (Otterbein et al., 1999b; Fujita et al., 2001; Sato et al.,
2001). These include its ability to bind the Fe atom in the pros-
thetic heme groups of hemoproteins, thereby modulating their
function (Kim et al., 2006; Piantadosi, 2008; Mustafa et al., 2009).
This mechanism of action probably underlies the cytoprotective
(Brouard et al., 2000; Silva et al., 2006) and “anti-inﬂammatory”
effects of CO (Otterbein et al., 2000) as well as the ability of
this gasotransmitter to inhibit platelet activation and aggregation
(Brune and Ullrich, 1987). In addition, binding of CO to the Fe-
heme prevents the oxidation of hemoproteins, thereby slowing
down heme release. When exerted over cell-free Hb (Hebbel et al.,
1988; Pamplona et al., 2007), CO prevents heme release from Hb,
suppressing the pathogenesis of severe forms of malaria (Pam-
plona et al., 2007; Ferreira et al., 2008). Presumably thismechanism
should contribute to prevent the pathogenesis and/or progression
of other immune-mediated inﬂammatory diseases associated with
heme release from hemoproteins (reviewed in Ferreira et al., 2008;
Gozzelino et al., 2010).
Biliverdin is converted into lipid phase antioxidant BR (Stocker
et al., 1987) by BV reductase (BVR; Figure 3; Singleton and Laster,
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1965; Kutty and Maines, 1981). The BV/BR system affords cyto-
protection against reactive oxygen species (ROS; Dore et al., 1999;
Baranano et al., 2002). Both free heme and BR are lipophilic,
suggesting that the antioxidant action of BR may limit lipid oxida-
tion by free heme. Presumably, the cytoprotective effect of BV/BR
contributes to their overall protective effect against a range of
immune-mediated inﬂammatory diseases (Yamashita et al., 2004;
Ollinger et al., 2005, 2007; Sarady-Andrews et al., 2005; Overhaus
et al., 2006; Wang et al., 2006).
The Fe released from the protoporphyrin IX ring of heme
(Figure 3) can catalyze the generation of ROS via Fenton chem-
istry (Fenton, 1894). Cells can neutralize this cytotoxic effect by
secreting Fe via Fe efﬂux pumps (Ferris et al., 1999; Baranano et al.,
2000) or by storing Fe inside ferritin (Figure 3; Eisenstein et al.,
1991; Harrison and Arosio, 1996; Baker et al., 2003), a multimeric
protein complex composed of a heavy/heart chain (FtH) and a
light/liver chain (FtL) that store up to 4500 Fe molecules (Har-
rison and Arosio, 1996). The FtH subunit possesses ferroxidase
activity that allows it to catalyze the conversion of Fe2+ into Fe3+,
required for Fe storage. FtH is cytoprotective against TNF (Ferris
et al., 1999; Berberat et al., 2003; Cozzi et al., 2003; Xie et al., 2005)
as well as heme-driven cytotoxicity (Balla et al., 1992). This salu-
tary effect relies on the ability of FtH to neutralize the pro-oxidant
activity of labile Fe, thereby preventing sustained JNK activa-
tion (Pham et al., 2004; Raffaella Gozzelino et al., unpublished
results). Presumably, the cytoprotective effect of FtH prevents the
pathogenesis of immune-mediated inﬂammatory diseases, such
as demonstrated originally for ischemia–reperfusion injury (IRI;
Berberat et al., 2003) and more recently for malaria (Raffaella
Gozzelino et al., unpublished results).
Heme transport and secretion
Proteins involved in heme transport or intracellular heme
scavenging (see Heme Transport) should regulate the pro-oxidant
effects of heme (Figure 1; reviewed in Schultz et al., 2010; Khan
and Quigley, 2011). Expression of the intracellular heme-binding
thioredoxin-dependent peroxidase (PRX-1) is induced transcrip-
tionally by heme as well as by oxidative stress (Immenschuh et al.,
1995, 2005). PRX1 negates the pro-oxidant effect of free heme,
preventing its deleterious effects (Immenschuh et al., 1995, 2005).
Expression of the ubiquitous heme exporter, FLVCR, can also
provide protection against cytotoxic free heme (Quigley et al.,
2004; Keel et al., 2008; reviewed in Khan and Quigley, 2011). The
Abcg2 transporter can export intracellular PPIX, delivering heme
to extracellular albumin (Szatmari et al., 2006) and as such may
be considered, together with FLVCR, as a therapeutic target to
promote cell survival against heme-mediated cytotoxicity.
HEME AND THE PATHOGENESIS OF INFECTIOUS DISEASES
Failure to control the deleterious effects of free heme can con-
tribute to the pathogenesis of a number of pathologies, associated
with heme release from Hb or other hemoproteins.
SEVERE SEPSIS
Severe sepsis develops froman exacerbated inﬂammatory response
to microbial infection, leading to systemic refractory hypotension,
disseminated intravascular coagulation, multiple end-stage organ
failure andultimately todeath (reviewed in Cohen,2002;Hotchkiss
and Karl, 2003). The mechanisms underlying the pathogenesis of
severe sepsis remains poorly understood (reviewed in Cohen, 2002;
Riedemann et al., 2003; Ulloa and Tracey, 2005). We have recently
identiﬁed heme as a central component in the pathogenesis of this
acute inﬂammatory disease (Larsen et al., 2010).
Severe sepsis driven by polymicrobial infection can be induced
experimentally in mice by cecal ligation and puncture (CLP; Rit-
tirsch et al., 2009). Disease progression is associated with RBC
deformation (poikilocytosis), accumulation of cell-free Hb and
free heme as well as with decreased concentration of Hp and Hx in
plasma (Larsen et al., 2010). Poikilocytosis (Piagnerelli et al., 2003;
Bain, 2005) and decreased concentration of Hx in plasma (Larsen
et al., 2010) are also observed in human sepsis. This indicates that
in the absence of overt hemolysis, signiﬁcant amounts of Hb can
be released from RBC resulting in heme accumulation in the cir-
culation. A number of factors can contribute to this (Kempe et al.,
2007; Lang et al., 2008), including deregulated plasma osmolarity,
acidosis, bacterial hemolysins (particularly Clostridium perfrin-
gens; Gutierrez et al., 1995), or free heme itself (Sil et al., 2004).
The pathophysiologic relevance of these ﬁndings is supported by
the observations that lethality driven by severe sepsis is associated
with decreased levels of Hx in plasma and that administration
of puriﬁed Hx, after the onset of lethal sepsis in mice, improves
host survival (Larsen et al., 2010). This suggests that targeting free
heme, such as using Hx, might be used therapeutically to treat
severe forms of sepsis.
As discussed above (see Pathophysiological Effects of Free
Heme) free heme sensitizes cells in parenchymal tissues to undergo
PCD in response to a variety of pro-oxidant and/or inﬂammatory
compounds (Seixas et al., 2009; Gozzelino et al., 2010; Larsen et al.,
2010). This cytotoxic effect might contribute to the development
of organ failure associatedwith severe sepsis. Thismay also explain
why therapeutic targeting of single pro-inﬂammatory molecules,
e.g., the cytokine TNF (Cohen and Carlet, 1996) or IL-1 (Opal
et al., 1997) have failed as a treatment for severe sepsis, while tar-
geting free heme may be a valuable therapeutic option, since heme
acts as a cytoxic catalyst for these aswell as other pro-inﬂammatory
molecules.
It should be noted that the accumulation of free heme in the
circulation of septic patients and mice does not have to derive
exclusively from the oxidation of cell-free Hb. It is possible that
heme b is released from the oxidation of other hemoproteins to
which it binds non-covalently, such as myoglobin released during
rhabdomyolysis associated with septic shock (Kumar et al., 2009).
MALARIA
Together with sepsis, malaria remains a major cause of morbidity
and mortality worldwide, in particular in subtropical countries
where it affects millions of individuals every year (Murray et al.,
2012). Malaria develops in response to Plasmodium infection, at a
speciﬁc stage of the life cycle of this protozoan parasite associated
with RBC lysis (Miller et al., 2002). This so-called “blood stage” of
infection is associated with hemolysis and hence with oxidation of
cell-free Hb and production of free heme (Ferreira et al., 2008).
All the clinical manifestations of malaria, from fever to respi-
ratory distress, circulatory collapse, abnormal bleeding, jaundice,
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hemoglobinuria, severe anemia, convulsions, prostration, and/or
impaired consciousness are associated with the blood stage of
infection (Idro et al., 2005) and as such with the accumulation
of cell-free Hb and heme in plasma. When an individual presents
with one or more of these symptoms, with no cause of disease
other than Plasmodium infection, he is deﬁned as developing a
severe form of malaria (Marsh et al., 1995; Maitland and Marsh,
2004).
That non-Hb bound heme contributes to the pathogenesis of
severe forms of malaria is suggested by the following observations
inmice. Severity of Plasmodium infection correlates with the accu-
mulation of cell-free Hb and non-Hb bound free heme in plasma
(Pamplona et al., 2007; Ferreira et al., 2008; Andrade et al., 2010a).
The same is true in humans (Andrade et al., 2010a). Free heme
is sufﬁcient to elicit the onset of severe forms of malaria in Plas-
modium infected mice (Pamplona et al., 2007; Ferreira et al., 2008,
2011; Seixas et al., 2009). Heme catabolism by HO-1 suppresses
the pathogenesis of severe forms of malaria in mice (Pamplona
et al., 2007; Seixas et al., 2009; Ferreira et al., 2011) and is asso-
ciated with the pathologic outcome of malaria in humans as well
(Andrade et al., 2010a; Sambo et al., 2010; Walther et al., 2012).
The pathologic effect of free heme is most probably driven by
the Fe atom released from the protoporphyrin ring of heme, either
through catabolism by HO-1 (Tenhunen et al., 1968) or via non-
enzymatic oxidative degradation (Schaefer et al., 1985; Nagababu
and Rifkind, 2000, 2004). The deleterious effects of labile Fe can
be countered by FtH (Balla et al., 1992), probably explaining why
FtHprevents the onset of severe formsof malaria inmice (Raffaella
Gozzelino et al., unpublished results).
HEME AND THE PATHOGENESIS OF NON-INFECTIOUS
IMMUNE-MEDIATED INFLAMMATORY CONDITIONS
HEMOLYTIC DISORDERS
A number of hereditary diseases associated with defects in RBC
function can lead to premature RBC senescence, associated with
increased hematophagocytosis as well as with the release of Hb and
heme into circulation. Heme toxicity may contribute to the clini-
cal complications of these diseases, as illustrated in this section for
sickle cell anemia and G6PD deﬁciency.
Sickle cell disease
Sickle cell disease is a molecular disease (Pauling et al., 1949)
caused by a single point mutation in the β chain of Hb
(β6Glu>Val), leading to the synthesis of a modiﬁed Hb variant
generally referred to as HbS (Williams et al., 2005a; Jallow et al.,
2009). Other sickle mutations include HbC (β6Glu> Lys; Modi-
ano et al., 2001) and HbE (β6Glu> Lys; Hutagalung et al., 1999).
When present in the homozygous form, the Hb β6Glu>Val
sickle mutation becomes pathologic, leading under low oxygen
pressure to Hb polymerization, RBC deformation (sickle shape),
shortened RBC half-live and eventually to hemolysis. This is asso-
ciated with Hb and heme release into circulation (Hebbel et al.,
1988;Reiter et al.,2002). Thediseasemanifests by a rangeof clinical
outcomes that include episodes of vascular occlusion/dysfunction
eventually leading to the development of stroke and/or renal
failure. Sickle cell anemia is also associated with tissue Fe overload,
presumably driven by chronic accumulation of free heme in the
circulation (Hebbel et al., 1988; Reiter et al., 2002).
Cell-free Hb is thought to contribute to the pathogenesis of
sickle cell anemia, essentially by scavenging NO (Reiter et al.,
2002), thereby promoting vasoconstriction, platelet aggregation
and expression of adhesion molecules associated with endothelial
cell activation (Belcher et al., 2003). Interaction of NO with cell-
free Hb also catalyzes the production of free radicals, promoting
Hb oxidation and heme release. Further oxidation of cell-free Hb
can lead to the formation of ferrylHb aggregates acting as a pro-
inﬂammatory agonist in the vascular endothelium (Silva et al.,
2009).
Expression of HO-1 or administration of exogenous CO coun-
ters the pathological outcome of sickle cell disease (Belcher et al.,
2006). Presumably this protective effect is mediated via inhibi-
tion of endothelial cell activation (Soares et al., 2004; Seldon et al.,
2007). In addition, this salutary effect may also be mediated via
inhibition of Hb oxidation, preventing heme release from cell-free
Hb. If this proves to be the case, then targeting cell-free Hb or free
heme inplasmausingHporHx should ameliorate the pathological
outcome of sickle cell disease as well.
When present in the heterozygous form, the Hb β6Glu>Val
sickle mutation is not pathogenic, conferring instead a net sur-
vival advantage to human population living in endemic areas of
malaria (Williams et al., 2005b). This protective effect acts via a
mechanism involving the accumulation of low (non-cytotoxic)
levels of free heme in plasma that induce the expression of HO-
1 via activation of the transcription factor NF-E2-related factor 2
(Nrf2; Ferreira et al., 2011). TheCOproduced via heme catabolism
by HO-1 binds to cell-free Hb and prevents the accumulation of
high levels (cytotoxic) of circulating free heme following Plasmod-
ium infection, thus suppressing the pathogenesis of severe forms
of malaria (Ferreira et al., 2011). This protective effect does not
interfere with parasite load revealing that sickle Hb confers tol-
erance against Plasmodium infection (Ferreira et al., 2011). That
is, it promotes host survival irrespectively of its pathogen load
(Medzhitov et al., 2012).
Glucose-6-P dehydrogenase deﬁciency
RBC lack mitochondria and as such cannot generate NAPDH via
oxidative phosphorylation. Glucose-6-phosphate dehydrogenase
(G6PD) catalyzes the ﬁrst step of the pentose phosphate path-
way of glucose metabolism, and is a critical mechanism for the
generation of reducing power via RBC NADPH. More than 140
G6PD mutations have been reported, leading to RBC oxidative
stress and eventually to varying degrees of hemolysis (reviewed in
Cappellini and Fiorelli, 2008). The clinical outcomes associated
with G6PD deﬁciency are revealed clinically by fatigue, jaundice
(i.e., hepatic damage), increased circulating unconjugated BR and
lactate dehydrogenase as well as reticulocytosis (Cappellini and
Fiorelli, 2008). Presumably, some of these clinical outcomes can
be explained by the release of Hb and heme into circulation,
associated to chronic or acute episodes of hemolysis.
G6PD deﬁciency is one of the most common enzyme mutation
in human populations (Mason, 1996) and is particularly prevalent
in geographical areas where malaria is endemic. This suggests that
mutations leading to the functional silencing of the human G6PD
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gene were naturally selected through evolution on the basis of
the survival advantage they provide against malaria, a major dri-
ving force in human evolution (Cappellini and Fiorelli, 2008). The
molecular mechanism via which G6PD mutations confer protec-
tion against Plasmodium infection are not clear but, as discussed
in the previous section, this is likely to be related to the mechanism
involved in the protection conferred by sickle Hb against malaria.
PATHOLOGICAL COMPLICATIONS OF PREGNANCY
The early stages of pregnancy in mammals are associated with
the induction of high levels of HO-1 expression by placental
trophoblasts, as demonstrated in mice, rats, and humans (Ihara
et al., 1998; Barber et al., 2001; Sollwedel et al., 2005; Zenclussen
et al., 2011). This suggested that expression of HO-1 might be
required to support early stages of pregnancy, a notion in keeping
with the observation that Hmox1 deletion causes pre-natal lethal-
ity in mice (Poss and Tonegawa, 1997b; Yet et al., 1999; Tzima
et al., 2009). Several studies have demonstrated that reduced HO-
1 expression and/or activity can promote miscarriages in rodents
as well as in humans (Zenclussen et al., 2003, 2005), which is also
the case for pre-eclampsia, probably the most severe pathologi-
cal complication associated to human pregnancy (Ahmed et al.,
2000).
A more detailed analysis of the mechanisms involved in pre-
natal lethality associated with Hmox1 deletion in mice revealed
that HO-1 is required to sustain placental formation and func-
tion and hence fetal development and success of the early stages
of pregnancy (Zenclussen et al., 2011). Presumably, the salutary
effect of HO-1 relies on its ability to prevent the accumulation of
free heme, generated in the placenta from the oxidation of cell-free
Hb. This notion is supported by the observation that impairment
of intrauterine fetal survival, driven by Hmox1 deletion, is associ-
ated with the accumulation of free heme in plasma, while heme
administration towild type (Hmox1+/+)mice is sufﬁcient per se to
impair fetal survival (Zenclussen et al., 2011). CO can be used ther-
apeutically to preventmiscarriages inmice, inhibitingheme release
from cell-free Hb and preventing the accumulation of circulating
free heme (Zenclussen et al., 2011). This is, to the best of our
knowledge, the ﬁrst demonstration that heme can participate in
the pathogenesis of an immune-mediated inﬂammatory condition
that is not driven by infection.
ISCHEMIA AND REPERFUSION INJURY
Ischemia and reperfusion injury act as a major cause of pathology
leading to myocardial infarction, stroke or damage associated
with organ transplantation, among others. Ischemia refers to a
more or less pronounced restriction of blood supply to a given
organ, associated with lower than physiological supply of several
essential molecules, including O2. In the event that blood ﬂow is
re-established, i.e., reperfusion, the ischemic tissue is confronted
with an abrupt delivery of O2 that cannot be readily used by the
mitochondrial electron transport chain. The excess O2 becomes
available to oxidative enzymes, e.g., NADPH oxidase, catalyzing
the generation of ROS, i.e., superoxide (O2•), hydrogen peroxide
(H2O2) and hydroxyl radical (OH•). Accumulation of ROS above
a certain threshold level causes oxidative stress, promoting PCD
and tissue damage (Zhang et al., 2007a).
Expression of HO-1 exerts strong protective effects against IRI
(reviewed in Soares and Bach, 2007), via a mechanism that is not
clear but is likely to involve the catabolismof deleterious free heme,
which is in keeping with the notion that hemolysis might act as an
inherent component of the pathogenesis of IRI. Presumably, the
cytotoxic effect of free heme contributes to promote tissue damage
associated with IRI, explaining the salutary effects of HO-1 (Shen
et al., 2005), CO (Fujita et al., 2001; Akamatsu et al., 2004) or FtH
(Berberat et al., 2003) against this pathologic process.
TRANSPLANTATION
Mouse grafts can survive indeﬁnitely when transplanted into
immunosuppressed rats (Miyatake et al., 1998). Long-term sur-
vival relies on a cytoprotective response elicited in the transplanted
organ, a phenomenon termed by Fritz H. Bach as “accommoda-
tion” (Soares et al., 1999). HO-1 expression in the transplanted
organ is required to promote accommodation (Soares et al., 1998,
1999), a salutary effect mediated at least partially by CO (Sato
et al., 2001; reviewed in Soares and Bach, 2007). While there are
probably several mechanisms that can contribute to explain the
salutary effects of HO-1 and CO in the context of organ trans-
plantation, these are likely mediated by the capacity of HO-1
to prevent the deleterious effect of free heme (see HO-Catalyzed
HemeDegradation above). This remains however to be established
experimentally.
TARGETING FREE HEME THERAPEUTICALLY TO TREAT
IMMUNE-MEDIATED INFLAMMATORY DISEASES
SYSTEMIC HEME TARGETING
Targeting heme proteins
While CO appears to be a major component of the protective
action exerted by HO enzymatic activity (Otterbein et al., 1999b;
Brouard et al., 2000, 2002; Fujita et al., 2001; Sato et al., 2001; Aka-
matsu et al., 2004; Soares et al., 2004), the mechanism underlying
the salutary effects of this gasotransmitter remain unclear. CO can
bind Fe2+ within the prosthetic heme groups of hemoproteins and
hence modulate their biologic function (see HO-Catalyzed Heme
Degradation). Presumably, this underlies the capacity of CO to
act in a cytoprotective manner (Brouard et al., 2000, 2002; Silva
et al., 2006) as well as to modulate macrophage activation (Otter-
bein et al., 2000) and to control cell proliferation (Otterbein et al.,
2003).
There is another major biological output associated with CO
binding to the Fe atom in the prosthetic heme groups of hemopro-
teins that contributes to the salutary effects of this gasotransmitter.
Namely, CO can inhibit Fe-heme oxidation, preventing as well
hemoprotein oxidation. This inhibits heme release fromhemopro-
teins, as demonstrated for Hb (Pamplona et al., 2007; Figure 4),
which is sufﬁcient per se to explain how this gasotransmitter pre-
vents the pathological outcome of malaria (Pamplona et al., 2007;
Ferreira et al.,2008;Rosenthal,2011). This suggests thatCOmaybe
used pharmacologically as a supportive therapy for the treatment
of life-threatening complications of malaria.
It is likely that in a similar manner to Hb, CO may also pre-
vent heme release from other hemoproteins such as myoglobin.
Whether this would limit the pathological outcome of diseases
associated with the accumulation of cell-free myoglobin, such
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FIGURE 4 |Therapeutic targeting of free heme. Free heme, and its
pathophysiological effects, might be targeted directly and indirectly, extra-
and intracellularly, by a range of mechanisms. Extracellularly, albumin and
the two naturally occurring acute phase proteins, Hp and Hx, can scavenge
cell-free Hb and free heme, respectively, whereas CO can prevent the
release of heme from Hb. Intracellularly, induction of HO-1 or FtH, might
target excess heme and labile Fe, respectively. Antioxidants such as BR
and the heme carrier protein PRX1, could prevent the participation of
heme-Fe in the generation of unfettered production of free radicals (ROS).
Speciﬁc heme transport between the intra- and extracellular
compartments, including Abcg2, FLVCR, HCP1 and HRG-1, might be
considered as potential, therapeutic targets to afford protection against
heme cytotoxicity. Abbreviations: Bcrp/Abcg2, breast cancer resistance
protein/ATP-binding cassette g2; BR, bilirubin; CO, carbon monoxide; Fe,
iron; FLVCR, feline leukemic virus receptor; FtH, ferritin; Hb, hemoglobin;
HCP1, heme carrier protein-1; Hp, haptoglobin; HO-1, heme oxygenase-1;
HRG-1, heme responsive gene-1; Hx, hemopexin; ROS, reactive oxygen
species.
as during rhabdomyolysis (Kumar et al., 2009), remains to be
established.
While the evidence for the therapeutic application of CO in a
number of diseases is solid, the clinical application of this gaseous
molecule poses a number of practical challenges. Recently, the
development of CO-releasing molecules (CORMs) received con-
siderable attention as an alternative means of CO delivery (Foresti
et al., 2005; Motterlini and Otterbein, 2010). A number of studies
have demonstrated that the therapeutic beneﬁts of CORMs mimic
or can even excel those of CO inhalation (Pena et al., 2012).
Targeting free heme using natural heme scavengers
Under pathologic conditions associated with severe, acute, or
chronic hemolysis, as occurs under certain infectious and non-
infectious inherited diseases (see Heme and the Pathogenesis of
Infectious Diseases and Heme and the Pathogenesis of Non-
Infectious Immune-Mediated Inﬂammatory Conditions), the
physiologic Hb and heme scavengers become saturated (Muller-
Eberhard, 1970; Larsen et al., 2010). Therefore, replenishing the
circulating stores of heme scavengers, thereby compensating for
the loss of heme scavenging capacity in plasma, may be used as a
therapeutic approach to target circulating free heme and prevent
its deleterious effects.
Two clinical trials demonstrated that the administration of
albumin, a heme scavenger, provides a signiﬁcant survival beneﬁt
to children developing severe forms of malaria (Maitland et al.,
2005; Akech et al., 2006). Similar data has recently been reported
in the context of severe sepsis (Delaney et al., 2011). Whether
the therapeutic beneﬁt of albumin is due to its heme scavenging
capacity remains to be established.
We have recently shown that exogenously administered Hx
can prevent the lethal outcome of severe sepsis in mice (Larsen
et al., 2010), suggesting that this may also be a viable therapeutic
intervention against sepsis and possibly against other pathologies
associated with a hemolytic component, such as malaria, sickle cell
disease or other inherited hemolytic disorders (Figure 4).
CELLULAR HEME TARGETING
Cellular targeting of hemoproteins or heme transporters may
counter the deleterious effects of intracellular accumulation of free
heme and, as such, limit tissue damage and ameliorate the patho-
logical outcomeof immune-mediated inﬂammatory diseases. This
may be accomplished by the pharmacological use of CO that in
a similar manner to other gasotransmitters can diffuse freely into
cells and, as such, target intracellular hemoproteins. In keeping
with this notion, the cytoprotective effect of CO (Brouard et al.,
2000) may in this manner limit tissue damage associated with
the pathological outcome of immune-mediated inﬂammatory dis-
eases (Otterbein et al., 2000; Fujita et al., 2001; Sato et al., 2001;
Akamatsu et al., 2004; Pamplona et al., 2007; Ferreira et al., 2011).
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Given that the cytoprotective effect of COacts via amechanism tar-
geting themitochondria (Queiroga et al., 2010;Wang et al., 2011) it
is possible that CO would also target mitochondrial hemoproteins
that play a central role in the execution of PCD, e.g., cythocrome c.
Targeting heme transport may also be used therapeutically
to prevent heme-driven tissue damage (Figure 4). This type of
approach is based on the assumption that the cytotoxic effects of
free heme aremediated via amechanism that involves its transport
by dedicated heme transporters. If this proves to be the case, then
targeting these transporters may provide salutary effects against
immune-mediated inﬂammatory diseases. The general principle
may be that favoring the activity of heme exporters, such as FLVCR
or Abcg2 may allow cells to secrete heme and, as such, to prevent
its pro-oxidant effects leading to PCD and tissue damage. In a
similar manner, inhibiting cellular heme import such as by target-
ing HRG-1 and/or HCP1 may also be used to limit intracellular
heme accumulation (Figure 4; Gozzelino et al., 2010).
Finally, intracellular heme might be targeted by the modulation
of HO-1 expression and/or activity. This has been shown using
recombinant virus-mediated overexpression of HO-1 in animal
models of disease. These include vasospasm following subarach-
noid hemorrhage in rats (Ono et al., 2002), transplantation of
myogenic precursor cells in pigs (Laumonier et al., 2008), IRI
following liver transplant in rats (Coito et al., 2002), hyperoxia-
induced lung injury in rats (Otterbein et al., 1999a), and ath-
erosclerotic diseases (Stocker and Perrella, 2006), as reviewed in
(Abraham et al., 2007).
Alternatively, the deleterious effects of cellular heme can be
neutralized by the therapeutic induction of endogenous HO-1, via
the delivery of non-cytotoxic levels of heme or heme-containing
proteins, e.g., by so-called preconditioning. In this manner, the
administration of Hb in rats prior to challenge, was shown to
improve survival in response to endotoxic shock (Otterbein et al.,
1995), liver injury and kidney failure following rhabdomyolysis
(Nath et al., 1992). Interestingly, a physiological example of heme
preconditioning is represented by sickle cell trait, in which indi-
viduals carry the HbS mutation (see Sickle Cell Disease) in the
heterozygous form (Williams et al., 2005a,b; Jallow et al., 2009).
This mutation confers protection against severe forms of malaria
due to the continuous release of low concentrations of heme into
circulation, thereby leading to induction of endogenous HO-1
expression and protection against Plasmodium infection (Ferreira
et al., 2011).
CONCLUSION
Although not highly cytotoxic per se, free heme sensitizes non-
hematopoietic cells to undergo PCD in response to a variety of
pro-inﬂammatory agonists. This unique pathophysiologic feature
relies on the capacity of heme to promote the production of
free radicals in an unfettered manner. Several protection mech-
anisms, regulating heme synthesis, catabolism and transport, can
be considered as possible therapeutic targets to prevent the dele-
terious effects of free heme. In keeping with this notion, tissue
damage control afforded by genes involved in heme and Fe metab-
olism, such as HO-1 and FtH, provide a “proof of principle” for
the therapeutic beneﬁts associated with neutralization of heme-
Fe cytotoxicity in the context of immune-mediated inﬂammatory
diseases.
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